American Journal of Ophthalmology
Volume 148, Issue 4 , Pages 619-622.e3 , October 2009

A Study of Interactions between Pharmaceutical Representatives and Ophthalmology Trainees

  • Yue Wang

      Affiliations

    • Department of Ophthalmology and Visual Science Yale University School of Medicine, New Haven, Connecticut
    • Department of Ophthalmology, The Johns Hopkins University, Baltimore, Maryland
    • ,
  • Ron A. Adelman

      Affiliations

    • Department of Ophthalmology and Visual Science Yale University School of Medicine, New Haven, Connecticut
    • Corresponding Author InformationInquiries to Ron A. Adelman, Department of Ophthalmology and Visual Science Yale University School of Medicine, 40 Temple Street, New Haven, CT 06510

,Accepted 12 May 2009.

References 

  1. Zuger A. Fever pitch: getting doctors to prescribe is big business. In: New York Times; January 11, 1999;p. 1;Section A
  2. Stolberg SG, Gerth J. High-tech stealth being used to sway doctor prescriptions. In: New York Times; November 16, 2000;p. 1;Section A
  3. Zuger A. When your doctor goes to the beach, you may get burned. In: New York Times; February 24, 2004;p. 5;Section F
  4. Angell M. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York, New York: Random House; 2004;
  5. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4–8
  6. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26:1183–1189
  7. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies (A controlled study of physicians who requested additions to a hospital drug formulary). JAMA. 1994;271:684–689
  8. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns (There's no such thing as a free lunch). Chest. 1992;102:270–273
  9. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551–557
  10. Keim SM, Sanders AB, Witzke DB, Dyne P, Fulginiti JW. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Ann Emerg Med. 1993;22:1576–181
  11. Schwartz TL, Kuhles DJ, Wade M, Masand PS. Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry. 2001;13:159–162
  12. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med. 2002;34:729–731
  13. SoRelle R. Tougher rules keep pharmaceutical reps out of EDs. Emerg Med News. 2004;26:1;36
  14. Lichter PR. Debunking myths in physician-industry conflicts of interest. Am J Ophthalmol. 2008;146:159–171
  15. Lichter PR. Continuing medical education, physicians, and Pavlov: can we change what happens when industry rings the bell?. Arch Ophthalmol. 2008;126:1593–1597
  16. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med. 1993;22:1593–1596
  17. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA. 2001;286:1994–1999
  18. Tuffs A. Only 6% of drug advertising material is supported by evidence. BMJ. 2004;328:485

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00349-3

doi: 10.1016/j.ajo.2009.05.011

American Journal of Ophthalmology
Volume 148, Issue 4 , Pages 619-622.e3 , October 2009

Article Tools

* Image Usage & Resolution